NEWSROOM
Stay current with MiRXES
Media Releases
18 June 2024
Singapore – 11 June 2024 – Mirxes is pleased to announce that our fully-owned subsidiary, Mirxes Japan, has secured a grant of up to 20 million yen (S$172,000) from the Japan External Trade Organization (JETRO). This grant is a testament of Mirxes Japan’s effort and growth in Japan, and will support the development and validation of a new non-invasive cancer biomarker screening test service specifically for the Japanese market.
24 May 2024
Singapore, 25 May 2024 – In a First-In-Singapore collaboration, leading RNA
technology company Mirxes and PULSE TCM, a renowned provider of traditional
Chinese Medicine (TCM) services, today launched the holistic “East Meets West”
Community Health Screening Pilot at Bukit Gombak. Witnessed by Ms Low Yen Ling,
Senior Minister of State, Ministry of Culture, Community and Youth, Ministry of Trade
and Industry, Mayor of South West District and Grassroots Adviser to Bukit Gombak Grassroots Organisations, this pilot represents a novel approach towards integrating contemporary Western precision diagnostic technology with Eastern TCM wisdom, aimed at creating an integrated approach to preventive and personalised healthcare for a Healthier Singapore.
13 May 2024
Singapore, 13 May 2024 – The National University Hospital (NUH) and Mirxes are proud to announce the official opening of the NUH DMOC@Biopolis, one of Singapore’s first publicprivate partnership centres for specialty molecular testing. The NUH DMOC@Biopolis is an extension of NUH’s Diagnostic Molecular Oncology Centre (DMOC) that co-locates and integrates with Mirxes’ clinical laboratory, M Diagnostics at Biopolis. The Centre was inaugurated today by Deputy Prime Minister, Coordinating Minister for Economic Policies, and Chairman of the National Research Foundation (NRF), Mr Heng Swee Keat.
Media Coverage
Stay informed and keep abreast with our media news.
24 January 2025
SINGAPORE, (24 January 2025) — 在中国有显著业务的新加坡生物科技公司觅瑞（MiRXES）星期五（1月24日）宣布，它的香港上市计划已获得中国证券监督管理委员会（CSRC）的“绿灯”。
13 January 2025
SINGAPORE, (13 January 2025) — Singapore-based RNA technology firm Mirxes has secured US$40 million in structured financing from CBC Group’s R-Bridge Healthcare Fund.
Collaborations
Our partnerships
14 June 2024
SINGAPORE, (14 June 2024) — To increase patient access to affordable, advanced genomic testing for cancer in Singapore, Thermo Fisher Scientific Inc., the world leader in serving science, the National University Hospital, Singapore (NUH) and Mirxes, a Singapore-headquartered RNA technology company have signed a Memorandum of Understanding (MoU) agreement today. The agreement formalizes the commitment to collaborate, develop and clinically validate advanced, next-generation sequencing (NGS) genomic testing solutions and cancer research tailored specifically to address the needs of the Southeast Asian population.
13 March 2024
IMMEDIATE RELEASE (13 March 2024) – PropNex, Singapore’s leading real estate agency, has partnered Let’s Get Healthy Pte Ltd (LGH), a social enterprise focused on strengthening community healthcare, and Mirxes, a Singapore-headquartered RNA technology and early cancer detection company, to provide a first-in-the-industry initiative aimed early detection and at ensuring their long-term health. This large-scale comprehensive free health screening is part of the Precision Community Screening (PCS) programme conceptualised by LGH, with the screening tests curated and partly sponsored by Mirxes, for a period of five years to all its 12,313* salespersons (*as at Council of Estate Agencies 8 March 2024) and close to 200 full-time staff.
Insights
Welcome to our knowledge base of insights in the frontiers of the biotech industry.
Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats — to great success.
SOCIAL MEDIA
- Genomics
- Clinical Sequencing
- Discovery Genomics
- Cancer Screening
- GASTROClear for Patients
- GASTROClear for Medical Professionals
- LUNGClear
- Cancer Treatment Selection
- APEX Tissue
- COMPASS Tissue
- Infectious Diseases
- Fortitude 2.1
- Fortitude 3.0
- Fortitude Syndromic Panel
- CoVClear Mutation Panel
- Swab & Saliva Collection
- RNA Extraction Kit & Instruments